Cabaletta Bio Inc: Financial Report Reveals Market Insights by Mark Eisenberg 30.03.2024 Delve into a comprehensive financial analysis of Cabaletta Bio Inc, a key player in the NASDAQ exchange, with a strong ...
FBIO Stock Soars: Fortress Biotech Beats Q4 Earnings by Mark Eisenberg 29.03.2024 Fortress Biotech's Q3 earnings per share of -53 cents exceeded the analyst estimate of -$1.97 while revenue of $19.95 million ...
Fortress Biotech Q4 Earnings Report: Analysts Predicted Loss by Mark Eisenberg 29.03.2024 Fortress Biotech Inc's shares dropped 27.9% this quarter, exceeding analysts' predicted loss of $1.97 per share.
Dermira Stays Steady at $18.75 Amid Market Fluctuations by Mark Eisenberg 28.03.2024 Discover the financial insights of Dermira, a biopharmaceutical company, and gain a deeper understanding of their stock performance and market ...
Moleculin Biotech Stock Coverage and Analysis at StockNews by Mark Eisenberg 28.03.2024 Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...
Moleculin Biotech Stock Receives “Sell” Rating – Analysts by Mark Eisenberg 28.03.2024 Atticus Wealth Management LLC buys stake in Moleculin Biotech as the firm sets a “sell” rating on the stock; MBRX ...
Sichuan Kelun-Biotech Biopharmaceutical: Lowered Expectations Post Results by Mark Eisenberg 28.03.2024 Losses are expected to increase by 32% to CN¥3.15 per share for Sichuan Kelun-Biotech Biopharmaceutical. This is a significant change ...
NextCure, Inc.: Promising Growth Potential or Risky Investment? by Mark Eisenberg 28.03.2024 NextCure, Inc. (NXTC) is a biopharmaceutical company focused on novel immunomedicines. Strong financials, positive outlook, and promising pipeline.
Ventyx Biosciences: Financial Report Reveals Growth Challenges by Terry Bingman 28.03.2024 Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...
Adial Pharmaceuticals, Inc. Financial Report: Analyzing Performance. by Mark Eisenberg 28.03.2024 Adial Pharmaceuticals, Inc. - A biopharmaceutical company focusing on addiction therapeutics. Stock faced challenges this year, with price drops. Leadership ...